Page 36 - IACC Newsletter October November 2013 Issue 13

Basic HTML Version

Indo-US Corporate News
Morgan Stanley to open Bangalore centre to service US parent
Morgan Stanley will open a new Global In-House Centre (GIC) in Bangalore that will provide outsourcing services to the
multi-billion dollar company’s parent in the US.
This new centre will be opened in 2014 and will complement Morgan Stanley’s GICs in Mumbai, the company said in a
statement. Commenting on the firm’s plans to grow its GIC capabilities and footprint in India, Bill Strong, Morgan Stanley’s
Co-CEO Asia Pacific, said the company had reviewed global options for building a new GIC that can provide a mass of
employees to support its global functions and saw value-add in expanding further our on-the-ground teams in India.
While this is a new investment, the company did not quantify the exact amount of investments. However, it added that
this new site in Bangalore is aligned with its continued focus on leveraging India’s skilled and diverse talent pool for the
company. Morgan Stanley has been present in India since 1993 and the back-office provides investment banking, asset
management and research, capital markets-related research and sales and trading advisory services to its global clients
that include high net worth individuals from 1,200 offices across 43 countries.
The firm will continue to grow its existing Mumbai-based centres, in addition to the new Bangalore centre, officials added.
Copyright © Kasturi & Sons Ltd, All Rights Reserved.
Five Indian pharma companies get US FDA approval for generic Cymbalta
Dr. Reddy's Laboratories, Lupin, Sun Pharma Global FZE, Aurobindo Pharma and Torrent Pharmaceuticals have received US
FDA approval for the first generic versions of Cymbalta (duloxetine delayed-release capsules), a prescription medicine
used to treat depression and other conditions. These companies received FDA approval to market duloxetine in various
“Healthcare professionals and consumers can be assured that these FDA-approved generic drugs have met our rigorous
standards,” said Kathleen Uhl, acting director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and
Research. “Generic drugs offer greater access to health care for many people.”
Depression is characterized by symptoms that interfere with a person's ability to work, sleep, study, eat, and enjoy once-
pleasurable activities. Episodes of depression often recur throughout a person's lifetime. Signs and symptoms of
depression include: depressed mood, loss of interest in usual activities, significant change in weight or appetite, insomnia
or excessive sleeping (hypersomnia), restlessness/pacing (psychomotor agitation), increased fatigue, feelings of guilt or
worthlessness, slowed thinking or impaired concentration, and suicide attempts or thoughts of suicide.
Duloxetine and other antidepressant drugs have a boxed warning describing the increased risk of suicidal thinking and
behavior during initial treatment in children, adolescents, and young adults ages 18 to 24. The warning also says data do
not show this increased risk in those older than 24 years and that patients ages 65 and older who take antidepressants
have a decreased risk of suicidal thinking and behavior.
The warning says depression and other serious psychiatric disorders themselves are the most important causes of suicide
and that close monitoring of patients starting these medications is necessary. Duloxetine must be dispensed with a patient
medication guide that describes important information about the drug’s uses and risks.